secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001437749-25-024960
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin preclin data: Annamycin shows efficacy in liver cancers; AML readout H2 2025
--------------------------------------------------------------------------------

- Annamycin demonstrated anti-tumor activity in orthotopic HCC models, colorectal liver metastases, and PDAC liver metastases.
- Preclinical data show targeted organ accumulation (liver, spleen, lungs, pancreas) vs doxorubicin; no cardiotoxicity seen.
- Prior clinical data: 32 of 42 subjects received >FDA lifetime max anthracycline without cardiotoxicity.
- Preliminary data readout for Annamycin in AML expected in second half of 2025.
- Data presented at Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925024960/0001437749-25-024960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925024960/mbrx20250805_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-024960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer